Form 4: BioXcel Therapeutics CFO Richard Steinhart Executes Stock Transactions Under 10b5-1 Plan

BioXcel Therapeutics' Chief Financial Officer, Richard Steinhart, executed multiple stock transactions, including the vesting of restricted stock units and sales of common stock, under a pre-arranged 10b5-1 trading plan.

Summary

• Richard Steinhart, the Chief Financial Officer of BioXcel Therapeutics, engaged in several transactions involving the company's stock.
• These transactions included the vesting of restricted stock units (RSUs) and the sale of common stock.
• The transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on December 14, 2023.
• On December 14, 2024, 521 RSUs vested, and on December 15, 2024, 562 RSUs vested.
• On December 16, 2024, 205 shares were sold at $0.36 per share, and 372 shares were sold at $0.358 per share.
• Following these transactions, Mr. Steinhart beneficially owns 20,932 shares of common stock.

Sentiment

Score: 5

Explanation: The document is a routine disclosure of stock transactions by an executive, which is neither positive nor negative in itself. The use of a 10b5-1 plan suggests a pre-planned strategy, which is neutral.

Risks

• The sale of shares by a company executive could be perceived negatively by the market, potentially impacting the stock price.
• The reliance on a 10b5-1 trading plan suggests a pre-determined strategy for selling shares, which may not always align with the company's best interests.

Industry Context

This filing is a routine disclosure of insider trading activity, which is common for publicly traded companies. It provides transparency into the transactions of company executives.

Comparison to Industry Standards

• The use of a 10b5-1 trading plan is a standard practice for executives to avoid accusations of insider trading.
• The vesting schedule of the RSUs is typical for executive compensation packages.
• The sale of shares by executives is a common occurrence and is not unusual.

Stakeholder Impact

• The transactions may have a minor impact on shareholders, as the sale of shares by an executive could be perceived negatively.
• The vesting of RSUs is part of the executive's compensation package and is not expected to have a significant impact on other stakeholders.

Key Dates

Keywords

BioXcel Therapeutics, Richard Steinhart, stock transactions, Form 4, restricted stock units, Rule 10b5-1, insider trading, CFO, BTAI